Research

The expertise and commitment of our R&D and management teams, alongside a fruitful collaborations with academic and independent research institutes and contract research organizations, contribute to Neurim Pharmaceuticals’ remarkable successes in drug discovery and development. Neurim Pharmaceuticals has one product registered, Circadin® – prolonged release melatonin for insomnia, and several molecules in the pipeline for the treatment of other CNS disorders. Paediatric Prolonged-Release Melatonin has successfully completed a Phase III clinical trial in neurodevelopmental disabled children suffering from sleep disorders. Neurim is advancing with regulatory submissions for this product. The company’s lead drug candidate Piromelatine (Neu-P11) is a novel compound under development for sleep and cognition in Insomnia and Alzheimer’s Disease. It has completed a Phase II clinical trial for insomnia. A Phase II randomized, placebo controlled dose ranging study is underway, that is intended to evaluate efficacy and safety of Piromelatine for cognitive skills global functioning and sleep in patients with mild to moderate Alzheimer’s Disease is under way. Two more of its compounds (for neuropathic pain Alzheimer’s, and Parkinson’s Disease) are expected to reach final preclinical stages in the near term.

Products

Circadin® 2mg: prolonged-release melatonin formulation, approved for use (up to 13 weeks) in treatment of primary insomnia characterized by poor quality of sleep in patients aged 55 years or over. Slenyto®: Slenyto® is indicated for the treatment of insomnia in children and adolescents aged 2-18 with Autism Spectrum Disorder (ASD) and/or Smith-Magenis Syndrome (SMS), where sleep hygiene measures have been insufficient.

  • Text size: A A A
  • Circadin
  • Recent news

    • Slenyto (PedPRM) is now available in France!
    • Slenyto (PedPRM) is now available in Denmark!
    • Slenyto (PedPRM) is now also available in Iceland!
  • Partners

    Partners